Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys-Reference-Cited by-同舟云学术

Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys

Published:2022-07 Issue:31 Volume:40 Page:4231-4241
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Hashimoto Masayuki,Nagata Noriyo,Homma Tomoyuki,Maeda Hiroki,Dohi Keiji,Seki Naomi M.,Yoshihara Ken,Iwata-Yoshikawa Naoko,Shiwa-Sudo Nozomi,Sakai Yusuke,Shirakura Masayuki,Kishida Noriko,Arita Tomoko,Suzuki Yasushi,Watanabe Shinji,Asanuma Hideki,Sonoyama Takuhiro,Suzuki Tadaki,Omoto Shinya,Hasegawa Hideki

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference33 articles.

1. Weekly epidemiological update on COVID-19 - 12 October 2021 (https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19--- 12-october-2021). Accessed October 17, 2021.

2. Prospects for a safe COVID-19 vaccine;Haynes;Sci Transl Med,2020

3. Mechanisms of SARS-CoV-2 transmission and pathogenesis;Harrison;Trends Immunol,2020

4. Structure of SARS-CoV-2 spike protein;Zhang;Curr Opin Virol,2021

5. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike;Liu;Nature,2020

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial;Vaccine;2024-06

2. Global Emergence of SARS-CoV2 Infection and Scientific Interventions to Contain its Spread;Current Protein & Peptide Science;2024-05

3. A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults;Scientific Reports;2024-04-29

4. Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys;Journal of Infection;2023-12

5. Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan;Vaccine: X;2023-12